Pramipexole dihydrochloride hydrate

SKU: orb1300317

Description

Pramipexole dihydrochloride hydrate

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 191217-81-9
• MW: 302.26
• Purity: 99.68%
• Formula: C₁₀H₁₇N₃S·2HCl·H₂O
• SMILES: O.Cl.CCCN[C@H]1CCc2c(C1)sc(N)n2.Cl
• Target: Dopamine Receptor
• Solubility: DMSO:3.46 mg/mL (11.45 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (3.31 mM);H2O:55 mg/mL (181.96 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• Target IC50:
  D2 receptor:3.9 nM (Ki)|D4 receptor:1.3 nM (Ki)|D2 receptor:2.2 nM (Ki)|D3 receptor:0.5 nM (Ki)
• In Vivo:
  Pramipexole (4-100 mM) significantly attenuated DA- or L-DOPA-induced cytotoxicity and apoptosis, an effect that was not inhibited b the D3 receptor antagonist, U-99194 A, o the D2 receptor antagonist, raclopride.Pramipexole also protected MES23. Cells from hydrogen peroxide-induced cytotoxicity in a dose-dependent manner. cytotoxicity.Pramipexole effectively inhibited melanin formation.Pramipexole was neur Protective against nigrostriatal dopamine neurons in hypoxic-ischemic and methamphetamine models. When incubated with SH-SY5Y cells and perfused into rat striatum, Pramipexole reduce the level of oxygen radicals produced by methylpyridinium ion (MPP+).Pramipexole also concentration dependently inhibite the opening of mitochondrial transporter pore induced by calcium, phosphate, or MPP+. Pramipexole dose Pramipexole dose-dependently decreased dopamine metabolite levels, while striatal dopamine levels remained unchanged.
• In Vitro:
  Pramipexole (4-100 mM) significantly attenuated DA- or L-DOPA-induced cytotoxicity and apoptosis, an effect that was not inhibited b the D3 receptor antagonist, U-99194 A, o the D2 receptor antagonist, raclopride.Pramipexole also protected MES23. Cells from hydrogen peroxide-induced cytotoxicity in a dose-dependent manner. cytotoxicity.Pramipexole effectively inhibited melanin formation.Pramipexole was neur Protective against nigrostriatal dopamine neurons in hypoxic-ischemic and methamphetamine models. When incubated with SH-SY5Y cells and perfused into rat striatum, Pramipexole reduce the level of oxygen radicals produced by methylpyridinium ion (MPP+).Pramipexole also concentration dependently inhibite the opening of mitochondrial transporter pore induced by calcium, phosphate, or MPP+. Pramipexole dose Pramipexole dose-dependently decreased dopamine metabolite levels, while striatal dopamine levels remained unchanged.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

Parkinson's, Mirapex, middle, neuroprotection, neurological, occlusion, inhibit, Inhibitor, legs, D3, D2S, D2L, D4, disease, Dopamine Receptor, Dopamine, DopamineReceptor, cerebral, artery, syndrome, transient, RLS, restless, Pramipexole dihydrochloride Hydrate, Pramipexole dihydrochloride hydrate, Pramipexole 2HCl, Pramipexole 2HCl Monohydrate, Pramipexole dihydrochloride, tMCAO, recovery

Compound Identifiers

PubChem CID

166589